Initially approved for malignancies like melanoma, renal cell carcinoma, and non-small-cell lung cancer, ICIs have more recently been investigated in ACC, because PD-L1 expression has been detected on both tumor and infiltrating immune cells [44]. Here, CD274 is linked to neoplasm.